FDA 483 - Ivers-Lee AG - March 22, 2023

Ivers-Lee AG, a drug repacker in Burgdorf, Switzerland, was cited with two observations during an FDA inspection. The observations highlight significant deficiencies in equipment cleaning procedures, including cleaning validation and record keeping, and the accuracy and review of master production and control records. These issues indicate a lack of adequate control over critical manufacturing processes and documentation.